Please provide your email address to receive an email when new articles are posted on . Induction therapy with twice-weekly rusfertide helped patients with polycythemia vera achieve target hematocrit ...

Silence Therapeutics advanced its RNAi drug for polycythemia vera, shared new Phase 2 trial updates, and reaffirmed a strong ...

Dear Dr. Roach: My husband was diagnosed with secondary polycythemia in 2011. His hematocrit test (HCT) was 57%. He was ...

Treatments with therapeutic phlebotomy and hydroxyurea are associated with improved overall survival and decreased risk of thrombosis in older patients with polycythemia vera, according to a recent ...

My husband was diagnosed with secondary polycythemia in 2011. His hematocrit test (HCT) was 57%. He was referred to a hematologist. The hematologist would order a phlebotomy when his HCT was high. My ...

Phlebotomy and hydroxyurea tied to improved survival, lower risk for thrombosis in older patients (HealthDay News) — Among older patients with polycythemia vera (PV), therapeutic phlebotomy and ...

ATLANTA -- Maintaining patients with polycythemia vera at hematocrit levels below 45% reduced thrombotic complications without increasing rates of other serious adverse events compared with a higher ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window PTG-300, a ...

Guidelines indicate that high-risk patients with polycythemia vera (PV) should be treated with phlebotomy and cytoreductive therapy—such as hydroxyurea or interferon-alfa—to reduce the ...

NEWARK, Calif., Dec. 12, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today presented updated data from two ongoing Phase 2 studies evaluating ...